Lilly to buy gene-editing partner Verve for up to $1.3 billion in cardiac care push
By Christy Santhosh and Sriparna Roy (Reuters) -Eli Lilly will acquire gene-editing startup Verve Therapeutics for up to $1.3 billion, the companies said on Tuesday, accelerating a push into experimental cardiovascular therapies. The companies were partnering to develop one-time, gene-editing therapies to reduce high cholesterol in people with heart disease, as part of Lilly’s efforts …
Lilly to buy gene-editing partner Verve for up to $1.3 billion in cardiac care push Read More »










